Defilade Capital Management
Latest statistics and disclosures from Defilade Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, PFE, VEEV, BMRN, PTCT, and represent 27.57% of Defilade Capital Management's stock portfolio.
- Added to shares of these 10 stocks: VEEV (+$42M), BMRN (+$39M), BAX (+$31M), PODD (+$27M), TMO (+$26M), ABT (+$26M), ASND (+$25M), SOLV (+$24M), MDT (+$24M), LLY (+$22M).
- Started 20 new stock positions in CRNX, BDTX, VEEV, PODD, GKOS, TMO, AGIO, NVST, LRMR, MDT. LIVN, ASND, BMRN, ENOV, SOLV, BAX, ABT, STAA, TYRA, TFX.
- Reduced shares in these 10 stocks: HSIC (-$46M), BDX (-$44M), RVMD (-$44M), DXCM (-$34M), , , DNLI (-$25M), ZBH (-$23M), ICUI (-$22M), ITGR (-$19M).
- Sold out of its positions in ALGN, Ascendis Pharma A S, BDX, BIIB, DXCM, ITGR, ISRG, NBIX, NUVL, HSIC. TNDM, BHVN.
- Defilade Capital Management was a net seller of stock by $-4.9M.
- Defilade Capital Management has $747M in assets under management (AUM), dropping by 4.88%.
- Central Index Key (CIK): 0002088557
Tip: Access up to 7 years of quarterly data
Positions held by Defilade Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Defilade Capital Management
Defilade Capital Management holds 39 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 6.3 | $47M | +88% | 39k | 1199.43 |
|
| Pfizer (PFE) | 5.7 | $43M | +21% | 1.8M | 24.08 |
|
| Veeva Sys Cl A Com (VEEV) | 5.6 | $42M | NEW | 237k | 177.47 |
|
| BioMarin Pharmaceutical (BMRN) | 5.2 | $39M | NEW | 682k | 57.22 |
|
| Ptc Therapeutics I (PTCT) | 4.7 | $35M | +15% | 434k | 81.57 |
|
| Baxter International (BAX) | 4.2 | $31M | NEW | 1.5M | 21.32 |
|
| Insmed Com Par $.01 (INSM) | 4.0 | $30M | +44% | 282k | 106.62 |
|
| Zimmer Holdings (ZBH) | 3.7 | $27M | -45% | 317k | 86.09 |
|
| Insulet Corporation (PODD) | 3.6 | $27M | NEW | 177k | 152.25 |
|
| Thermo Fisher Scientific (TMO) | 3.5 | $26M | NEW | 52k | 501.36 |
|
| Abbott Laboratories (ABT) | 3.5 | $26M | NEW | 286k | 90.74 |
|
| Ascendis Pharma A/s Ord Shs (ASND) | 3.4 | $25M | NEW | 95k | 266.72 |
|
| Solventum Corp Com Shs (SOLV) | 3.3 | $24M | NEW | 317k | 77.15 |
|
| Medtronic SHS (MDT) | 3.2 | $24M | NEW | 303k | 78.23 |
|
| Elanco Animal Health (ELAN) | 2.8 | $21M | -7% | 864k | 24.61 |
|
| Agios Pharmaceuticals (AGIO) | 2.7 | $20M | NEW | 547k | 37.11 |
|
| Envista Hldgs Corp (NVST) | 2.6 | $19M | NEW | 726k | 26.35 |
|
| Revolution Medicines (RVMD) | 2.1 | $16M | -73% | 83k | 187.28 |
|
| ICU Medical, Incorporated (ICUI) | 2.1 | $16M | -58% | 106k | 146.60 |
|
| Cogent Biosciences (COGT) | 2.0 | $15M | +11% | 393k | 38.70 |
|
| Lantheus Holdings Inc Common Stock Usd 0.01 (LNTH) | 2.0 | $15M | -46% | 133k | 110.94 |
|
| Ocular Therapeutix (OCUL) | 2.0 | $15M | 1.5M | 9.82 |
|
|
| Eledon Pharmaceuticals (ELDN) | 1.9 | $14M | 3.5M | 3.94 |
|
|
| Tyra Biosciences (TYRA) | 1.6 | $12M | NEW | 377k | 31.94 |
|
| Olema Pharmaceuticals (OLMA) | 1.5 | $12M | -38% | 925k | 12.51 |
|
| Oric Pharmaceuticals (ORIC) | 1.5 | $11M | +24% | 1.0M | 10.83 |
|
| Larimar Therapeutics (LRMR) | 1.5 | $11M | NEW | 3.7M | 3.05 |
|
| Globus Med Cl A (GMED) | 1.5 | $11M | -60% | 140k | 79.01 |
|
| Colfax Corp (ENOV) | 1.5 | $11M | NEW | 532k | 20.70 |
|
| Evommune Com Shs (EVMN) | 1.4 | $11M | +16% | 793k | 13.29 |
|
| Teleflex Incorporated (TFX) | 1.4 | $10M | NEW | 80k | 126.76 |
|
| Denali Therapeutics (DNLI) | 1.3 | $10M | -71% | 392k | 25.72 |
|
| Glaukos (GKOS) | 1.2 | $9.3M | NEW | 67k | 139.76 |
|
| Staar Surgical Com Par $0.01 (STAA) | 1.2 | $9.2M | NEW | 322k | 28.69 |
|
| Pacs Group Com Shs (PACS) | 1.2 | $9.2M | -64% | 216k | 42.64 |
|
| Crinetics Pharmaceuticals In (CRNX) | 1.2 | $9.0M | NEW | 239k | 37.42 |
|
| Livanova SHS (LIVN) | 1.2 | $8.8M | NEW | 107k | 82.23 |
|
| Black Diamond Therapeutics (BDTX) | 0.4 | $3.1M | NEW | 1.7M | 1.85 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 0.3 | $2.4M | 7.6M | 0.32 |
|
Past Filings by Defilade Capital Management
SEC 13F filings are viewable for Defilade Capital Management going back to 2026
- Defilade Capital Management 2026 Q2 filed Aug. 14, 2026
- Defilade Capital Management 2026 Q1 restated filed June 12, 2026